Medisafe 1 Technologies Board of Directors Approves Development of New Products for Intravenous Infusion and Blood Banks

JERUSALEM, November 22, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's board of directors has approved the research and development of two new medical locking device products.

In addition to the company's patented syringe locking device, the company will now seek to develop bar-coded locking devices for intravenous infusion bags, as well as blood transfusion bags.

It is estimated that the new technology will be ready for demonstration within three months' time.

The locking devices will physically prevent the intravenous administration of medications or blood, unless the prescribed dosages and/or blood type of the intended patient are first confirmed electronically.

"Human errors, both the improper labeling of bags as well as improper administration, are among the leading causes of blood transfusion related deaths," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "Applying the concepts behind our patented syringe bar-coding and locking device technology to transfusion and infusion bags can contribute to a reduction in the number of preventable deaths in hospitals.

"In addition, this technology can significantly reduce legal malpractice and hospital insurance fees," Elhadad added.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

    Contact:
    Jacob Elhadad
    CEO
    +972-524440000
    [email protected]

SOURCE Medisafe 1 Technologies Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED